1. Home
  2. SHLS vs WVE Comparison

SHLS vs WVE Comparison

Compare SHLS & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shoals Technologies Group Inc.

SHLS

Shoals Technologies Group Inc.

HOLD

Current Price

$8.11

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$21.18

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHLS
WVE
Founded
1996
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
SHLS
WVE
Price
$8.11
$21.18
Analyst Decision
Buy
Strong Buy
Analyst Count
19
14
Target Price
$9.42
$25.93
AVG Volume (30 Days)
4.1M
11.1M
Earning Date
11-04-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.19
N/A
Revenue
$433,993,000.00
$109,230,000.00
Revenue This Year
$20.62
N/A
Revenue Next Year
$18.88
$31.09
P/E Ratio
$42.50
N/A
Revenue Growth
2.68
103.75
52 Week Low
$2.71
$5.28
52 Week High
$11.36
$21.73

Technical Indicators

Market Signals
Indicator
SHLS
WVE
Relative Strength Index (RSI) 46.35 90.63
Support Level $7.68 $6.93
Resistance Level $8.39 $7.78
Average True Range (ATR) 0.44 1.10
MACD 0.04 1.33
Stochastic Oscillator 69.60 97.16

Price Performance

Historical Comparison
SHLS
WVE

About SHLS Shoals Technologies Group Inc.

Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: